Newswire (Published: Friday, November 23, 2018, 10:00:00 AM CST, Received: Friday, November 23, 2018, 2:36:04 PM CST)

Word Count: 428

By a News Reporter-Staff News Editor at Drug Week -- Current standard imaging techniques for initial staging of prostate cancer often underestimate the extent of disease beyond the prostate. A study featured in The Journal of Nuclear Medicine's November issue demonstrates that prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can pinpoint prostate cancer locations with superior accuracy. More accurate detection makes more precisely targeted treatment possible. Men with non-metastatic disease who chose radiotherapy could, therefore, improve their chances of a successful outcome with PSMA PET/CT imaging to more accurately define the areas targeted for irradiation (see also Society of Nuclear Medicine and Molecular Imaging).

"The planning of radiotherapy for prostate cancer starts with precise delineation of the anatomic targets for delivery of radiotherapy," explains Nicholas G. Nickols, MD, PhD, of UCLA and the VA Greater Los Angeles Healthcare System in Los Angeles, California. "The prostate is always included in the irradiated volume, but there is currently no consensus about whether pelvic lymph nodes that appear to be free of cancer on standard imaging should also be irradiated." He states, "Incorporation of PSMA PET/CT into the process of radiotherapy planning might improve the success rate of curative-intent prostate radiotherapy by identifying patients with occult (invisible to conventional imaging) metastatic disease or local (pelvic) disease that is not visible on conventional imaging and modifying target volumes and dose to adequately cover and control local disease."

In this project, 73 patients with localized prostate cancer and no prior local therapy underwent gallium-68 (68Ga)-PSMA-11 PET/CT scans. All patients had PSMA-positive primary prostate lesions. In addition, 25 of the 73 (34 percent) had PSMA-positive pelvic nodal metastases, and 7 (9.5 percent) had PSMA-positive distant metastases. PSMA-positive lesions not covered by planning volumes based on the clinical target volumes from standard imaging were considered to have a major potential impact on treatment planning.

Nickols reports, "We found that addition of the information from PSMA PET/CT to standard imaging had a major impact on the planning of curative-intent prostate radiotherapy for 16.5 percent to 37 percent of patients, depending on if one initially elects to target pelvic nodes that are free of disease on conventional imaging." He adds, "These findings represent another convergence of molecular imaging and precision radiotherapy. PSMA PET/CT offers unprecedented accuracy and sensitivity for detecting the location of prostate cancer within a patient, and modern radiotherapy offers a non-invasive and generally safe method for delivering a tumoricidal dose of radiotherapy to the targeted cancer."

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Society of Nuclear Medicine and Molecular Imaging
University of California Los Angeles

Industries

Healthcare
      Medical Devices
            Medical Diagnostic Equipment
                  Medical Imaging Equipment
            Medical Treatment Devices
                  Radiosurgery Devices
Manufacturing
      Medical Device Manufacturing
            Medical Devices
                  Medical Diagnostic Equipment
                        Medical Imaging Equipment
                  Medical Treatment Devices
                        Radiosurgery Devices

Places

North America
United States
Americas
California
Los Angeles

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Blood Disorders
                  Leukemia and Hematological Cancer
            Cancer
                  Leukemia and Hematological Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Medical Specialties and Practices
            Radiology
                  Nuclear Medicine
      Treatments and Therapies
            Radiation Therapy